THE PLACE OF ENZALUTAMIDE IN THE SERIAL TREATMENT OF TREATMENT-RESISTANT PROSTATE CANCER

Prostate cancer initially responds to androgen-deprivation therapy, but most patients eventually develop a castration-resistant form of disease. Enzalutamid is the superselective inhibitor of the androgen receptor (AR), which blocks several stages of the AR signal path. The drug showed significant e...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: A. A. GRITSKEVICH, S. V. MISHUGIN, I. G. RUSAKOV
Format: Artigo
Langue:Russo
Publié: Remedium Group LLC 2017-06-01
Collection:Медицинский совет
Sujets:
metastatic cancer
enzalutamide
abiraterone acetate
castration resistance
Accès en ligne:https://www.med-sovet.pro/jour/article/view/1894
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires